This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2025 Nov 20;393(20):2067.

doi: 10.1056/NEJMc2513141.

Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply

W Timothy Garvey¹, Cynthia Karenina Osorto Contreras², Melanie J Davies³

Affiliations

Affiliations

¹ University of Alabama at Birmingham, Birmingham.
² Novo Nordisk, Søborg, Denmark.
³ University of Leicester, Leicester, United Kingdom.

PMID: 41259768
DOI: 10.1056/NEJMc2513141

Comment

Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply

W Timothy Garvey et al. N Engl J Med. 2025.

. 2025 Nov 20;393(20):2067.

doi: 10.1056/NEJMc2513141.

Authors

W Timothy Garvey¹, Cynthia Karenina Osorto Contreras², Melanie J Davies³

Affiliations

¹ University of Alabama at Birmingham, Birmingham.
² Novo Nordisk, Søborg, Denmark.
³ University of Leicester, Leicester, United Kingdom.

PMID: 41259768
DOI: 10.1056/NEJMc2513141

No abstract available

PubMed Disclaimer

Comment on

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH; REDEFINE 1 Study Group. Garvey WT, et al. N Engl J Med. 2025 Aug 14;393(7):635-647. doi: 10.1056/NEJMoa2502081. Epub 2025 Jun 22. N Engl J Med. 2025. PMID: 40544433 Clinical Trial.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon